9 Meters Biopharma (NASDAQ:NMTR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.
Risk & Volatility
9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Earnings and Valuation
This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
9 Meters Biopharma | N/A | N/A | $-27,050,000.00 | N/A | N/A |
Enanta Pharmaceuticals | $122.47 million | 8.03 | $-36,170,000.00 | ($0.89) | -54.78 |
9 Meters Biopharma has higher earnings, but lower revenue than Enanta Pharmaceuticals.
Insider & Institutional Ownership
19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Enanta Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
9 Meters Biopharma | 0 | 0 | 7 | 0 | 3.00 |
Enanta Pharmaceuticals | 1 | 3 | 3 | 0 | 2.29 |
9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Enanta Pharmaceuticals has a consensus price target of $65.2857, suggesting a potential upside of 33.92%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Enanta Pharmaceuticals.
Profitability
This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
9 Meters Biopharma | N/A | N/A | -258.66% |
Enanta Pharmaceuticals | -29.53% | -3.75% | -3.53% |
Summary
9 Meters Biopharma beats Enanta Pharmaceuticals on 7 of the 11 factors compared between the two stocks.